cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Part of paid clinical trials in Duarte, California.
- Sponsor
- Adela, Inc
- Study ID
- NCT05366881
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - N/A
- Healthy Volunteers
- Accepted
Study Details
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care. Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in lung cancer. This cancer was selected based on the existing clinical landscape and treatment availability.
Key Dates
- Start date
- May 3, 2022
- Status verified
- Jan 2026
- Primary completion
- Mar 31, 2026
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 7,000 participants (estimated)
Arms
- Arm: CasesCases will include participants with newly diagnosed, treatment-naive cancer at the time of enrollment.
- Arm: ControlsControls will include participants without known cancer at the time of enrollment.
Primary Outcome Measure
Detection of cancer [ Time Frame: 24 months ]
Central Contacts
- Brian Allen, MS203-514-4155
- Michelle Anderson475-766-8183
Locations (17)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | Gregory Idos, MD (PRINCIPAL_INVESTIGATOR) |
| Miami Cancer Institute | Miami | Florida | 33176 | Belkys Salinas Manmeet Ahluwalia, MD (PRINCIPAL_INVESTIGATOR) |
| North Georgia Health System | Gainesville | Georgia | 306501 | Trena Davis Charles Nash, MD (PRINCIPAL_INVESTIGATOR) |
| Baptist Floyd | New Albany | Indiana | 47150 | Tasha Dodson Amitoj Gill, MD (PRINCIPAL_INVESTIGATOR) |
| Baptist Corbin | Corbin | Kentucky | 40701 | Janie Platt Abigail Byrnes, MD (PRINCIPAL_INVESTIGATOR) |
| Baptist Hardin | Elizabethtown | Kentucky | 42701 | Amy Steward Christopher Burkeen, MD (PRINCIPAL_INVESTIGATOR) |
| Baptist Lexington | Lexington | Kentucky | 40503 | Janie Platt Arvinda Padmanabhan, MD (PRINCIPAL_INVESTIGATOR) |
| Baptist Paducah | Paducah | Kentucky | 42003 | - |
| Allina Health Cancer Institute | Minneapolis | Minnesota | 55407 | Joleen Hubbard, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic | Rochester | Minnesota | 55902 | Angela R Emanuel Lisa A Boardman, MD (PRINCIPAL_INVESTIGATOR) |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Peter Mazzone, MD, MPH (PRINCIPAL_INVESTIGATOR) |
| Oregon Health Sciences University | Portland | Oregon | 97201 | Diana Potts Nima Nabavizadeh, MD (PRINCIPAL_INVESTIGATOR) |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | Andrew M Chen Gerard Silvestri, MD (PRINCIPAL_INVESTIGATOR) |
| McLeod Health | Florence | South Carolina | 29502 | Betsy Harris Virginia Clyburn-Ipock, MD (PRINCIPAL_INVESTIGATOR) |
| Baptist (BHMCC) | Memphis | Tennessee | 38120 | Tracy Stewart Philip Lammers, MD (PRINCIPAL_INVESTIGATOR) |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37203 | Anna Dumont Brian Rini, MD (PRINCIPAL_INVESTIGATOR) |
| Elligo Health Research, Inc. | Austin | Texas | 78704 | Cynthia Currasco Faith Holmes, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Duarte, CA
Related Studies
- Bone Marrow Grafting for Leukemia and LymphomaEnrolling By Invitation · Stanford University · Stanford, California
- Identification and Characterization of Novel Proteins and Genes in Head and Neck CancerRecruiting · Stanford University · Stanford, California
- Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenRecruiting · M.D. Anderson Cancer Center · Miami, Florida
- Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung CancersRecruiting · Stanford University · Stanford, California